DV
Dividend Vision

SPRO — Spero Therapeutics Inc

Spero Therapeutics Inc (SPRO)

Total return is -89.3% over the past 8.8 years, 334.4 points behind SPY at 245.1%. Its deepest 1-year drawdown was 61.4%.

SPRO is an equity stock that tracks Spero Therapeutics Inc, a single-company holding rather than a diversified ETF. The fund does not currently offer distributions or a dividend yield, making it unsuitable for income-focused investors. This holding appeals primarily to investors seeking direct equity exposure to a biopharmaceutical company rather than those pursuing dividend income or passive index-tracking strategies.

SPRO key facts

Asset type
Stock
Asset class
Equity
Inception date
11/02/2017
Last close
$1.23
Market cap
$83,378,152
Average volume
744545.0
Beta
1.493
Payout ratio
0.0
P/E ratio
5.3333
Forward P/E
0.0
EPS
$0.27